Four anti-CD19 CAR T-cell therapies (KymriahTM, TecartusTM, YescartaTM, and BreyzaniTM) are presently authorized for the treatment of BCL, follicular lymphomas, and MCL [97]. The gene discussed is CD19; the disease is mantle cell lymphoma.